Alzheimer Disease
📧 Sign up to get email alerts when something new happens for Alzheimer Disease.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2012-10-02Clinical Trial Update: An Extension To The B1451006 Protocol To Evaluate The Safety and Efficacy of Dimebon In Subjects With Moderate-to-Severe Alzheimer's Disease [Phase 3]
Pfizer conducted an extension of the Phase 3 B1451006 protocol to evaluate the safety and efficacy of Dimebon (latrepirdine) in moderate-to-…
-
CLINICAL_TRIALS trial_result · 2012-10-02Clinical Trial Update: A Phase 3 Efficacy Study Of Dimebon In Patients With Moderate To Severe Alzheimer's Disease [Phase 3]
Pfizer terminated a Phase 3 efficacy study of Dimebon (latrepirdine) for Alzheimer's disease; results were posted in 2012.
-
CLINICAL_TRIALS trial_result · 2012-10-01Clinical Trial Update: The Long-Term Safety and Efficacy Follow-Up Study of Subjects Who Completed the Phase I Clinical Trial of Neurostem®-AD
This clinical trial update reports the long-term safety and efficacy follow-up of subjects who completed the Phase I study of Neurostem-AD.
-
CLINICAL_TRIALS trial_result · 2012-09-28Clinical Trial Update: Efficacy and Tolerability of MLC601 in Patients With Mild to Moderate Alzheimer Disease Who Were Unable to Tolerate or Failed to Benefit From Treatment With Rivastigmine [Phase 2]
A Phase 2 study evaluating the efficacy and tolerability of MLC601 in patients with mild to moderate Alzheimer's disease who were unable to …
-
CLINICAL_TRIALS trial_result · 2012-09-28Clinical Trial Update: Phase II Study for Amyloid Binding Imaging Study of [18F]AV-45 in Patients With Mild Cognitive Impairment, Alzheimer's Disease and Healthy Volunteers [Phase 2]
Phase II imaging study evaluating [18F]AV-45 (florbetapir) for amyloid imaging in patients with mild cognitive impairment and Alzheimer's di…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2012-09-28Clinical Trial Update: Randomized Trial of Exercise and Social Interaction in a Community-Based Sample of Non-Demented Chinese Elders [NA]
This randomized trial assessed the combined effects of exercise and social interaction in a community-based sample of non-demented Chinese e…
-
CLINICAL_TRIALS trial_result · 2012-09-28Clinical Trial Update: Clinical Research Center for Dementia of South Korea (CREDOS)(or CRCD)
Clinical trial update for the Clinical Research Center for Dementia of South Korea (CREDOS/CRCD) at Samsung Medical Center, involving Alzhei…
-
EMA withdrawal · 2012-09-27EMA Withdrawn: Rivastigmine Teva (rivastigmine) — Teva Pharma B.V.
The EMA withdrew Rivastigmine Teva (rivastigmine) from its European market authorization.
-
CLINICAL_TRIALS trial_result · 2012-09-26Clinical Trial Update: Effect of PF-04360365 On ABETA In Patients With Alzheimer's Disease And Healthy Volunteers [Phase 1]
A Phase 1 trial evaluating the effect of PF-04360365 on amyloid-beta in patients with Alzheimer's disease and in healthy volunteers.
-
CLINICAL_TRIALS trial_result · 2012-09-25Clinical Trial Update: A Biomarker Study of Solanezumab in Patients With and Without Alzheimer's [Phase 2]
A Phase 2 biomarker study evaluating solanezumab in patients with and without Alzheimer's disease has completed.
-
CLINICAL_TRIALS trial_result · 2012-09-25Clinical Trial Update: Effect of LY2062430 on the Progression of Alzheimer's Disease [Phase 3]
Phase 3 trial evaluating LY2062430 for Alzheimer's disease has completed.
-
EMA guidance · 2012-09-20World Alzheimer's Month: September 2012
A European Medicines Agency feature highlighting World Alzheimer’s Month in September 2012, with information and messaging related to Alzhei…
-
CLINICAL_TRIALS trial_result · 2012-09-19Clinical Trial Update: Comparative Efficacy, Safety, and Tolerability of Rivastigmine 10 and 15 cm^2 Patch in Patients With Alzheimer's Disease (AD) Showing Cognitive Decline [Phase 3]
Phase 3 trial comparing two rivastigmine transdermal patch doses (10 cm^2 vs 15 cm^2) in Alzheimer’s disease patients with cognitive decline…
-
CLINICAL_TRIALS trial_result · 2012-09-14Clinical Trial Update: SNIFF 120: Study of Nasal Insulin to Fight Forgetfulness (120 Days) [Phase 2]
A Phase 2 trial (SNIFF 120) tested intranasal insulin for forgetfulness in people with Mild cognitive impairment and Alzheimer's disease; th…
-
CLINICAL_TRIALS research · 2012-09-13Clinical Trial Update: Non-expensive and Widely Available Tests as Diagnostic Tools in Dementia and Their Ability to Predict Disease Progression
A clinical trial update discusses the use of non-expensive, widely available tests as diagnostic tools in dementia and their potential to pr…
-
FDA approval · 2012-09-04FDA Approved: ARICEPT — Supplemental Application (Eisai Inc.)
FDA approved a supplemental application for ARICEPT (donepezil hydrochloride) submitted by Eisai Inc., resulting in changes to the product's…
-
FDA approval · 2012-09-04FDA Approved: ARICEPT — Supplemental Application (Eisai Inc.)
FDA approved a supplemental application for Aricept (donepezil hydrochloride) from Eisai Inc.
-
FDA approval · 2012-08-31FDA Approved: RIVASTIGMINE — Supplemental Application (Sandoz Inc)
FDA approved a supplemental application for rivastigmine submitted by Sandoz Inc.
-
CLINICAL_TRIALS trial_result · 2012-08-30Clinical Trial Update: Safety Study of HPP854 in Subjects With Mild Cognitive Impairment or a Diagnosis of Mild Alzheimer's Disease [Phase 1]
A Phase 1 safety study of HPP854 in subjects with mild cognitive impairment or mild Alzheimer's disease has been terminated.
-
CLINICAL_TRIALS trial_result · 2012-08-29Clinical Trial Update: Safety and Tolerability of Memantine in Moderate to Severe Alzheimer's Disease [Phase 3]
Phase 3 trial assessing safety and tolerability of memantine in moderate to severe Alzheimer's disease; the study was terminated and results…
-
CLINICAL_TRIALS trial_result · 2012-08-22Clinical Trial Update: Exploratory and Safety Study of [F-18]W372 [EARLY_Phase 1]
Siemens Molecular Imaging completed an exploratory and safety Phase 1 study of the PET tracer [F-18]W372 for Alzheimer's disease.
-
FDA approval · 2012-08-17FDA Approved: DONEPEZIL HYDROCHLORIDE — Original Application (Macleods Pharmaceuticals Limited)
FDA approves a generic donepezil hydrochloride product for Alzheimer's disease under an Original Application (ANDA). The applicant is Macleo…
-
CLINICAL_TRIALS trial_result · 2012-08-14Clinical Trial Update: A Trial of 18F-AV-133 and 18F-AV-45 Positron Emission Tomography (PET) [Phase 1, Phase 2]
A clinical trial update reports completion of Phase 1 and Phase 2 studies evaluating PET tracers 18F-AV-133 and 18F-AV-45 for imaging dement…
-
CLINICAL_TRIALS trial_result · 2012-08-14Clinical Trial Update: The CIRCADIAN Study: Evaluation of Modulating Effect of Galantamine on Circadian Rhythm in Patients With Mild to Moderate Alzheimer's Disease [Phase 4]
Phase 4 trial evaluating whether galantamine can modulate circadian rhythm in patients with mild to moderate Alzheimer's disease; the study …
-
CLINICAL_TRIALS research · 2012-08-08Clinical Trial Update: Thalidomide for Patients With Mild to Moderate Alzheimer's Disease [Phase 2, Phase 3]
An update on a Phase 2/3 clinical trial evaluating thalidomide for Alzheimer's disease.